<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151433</url>
  </required_header>
  <id_info>
    <org_study_id>S62899</org_study_id>
    <nct_id>NCT04151433</nct_id>
  </id_info>
  <brief_title>Conservative Endometrioma Surgery</brief_title>
  <acronym>BLAST</acronym>
  <official_title>BLAST: a Randomized Controlled Trial on Conservative Endometrioma Surgery Using the CO2 Laser: the Combined Technique Versus CO2 Laser Vaporization Only</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GZA Ziekenhuizen Campus Sint-Augustinus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHR La Citadelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study which surgical technique offers better results in treating endometriomas in terms of
      ovarian reserve preservation.

      The 2 conservatives techniques used are:

        1. The combined technique

        2. CO2 laser vaporization only

      Ovarian reserve will be assessed by consecutive measurements of AMH serum levels before and
      after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AMH levels 3 months postoperatively</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>To assess the effect of conservative laparoscopic treatment of endometrioma(s) on ovarian reserve as reflected by AMH in patients planned for laparoscopic CO2 laser surgery. For the primary outcome evaluation of serum AMH will be done before (baseline) and after (at 3 months follow up) laparoscopic treatment of endometrioma(s).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Endometriosis Ovary</condition>
  <condition>Endometrioma</condition>
  <arm_group>
    <arm_group_label>The combined technique</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First step consisting of stripping the cyst wall for 80% of the surface, followed by a second step consisting of ablation of the remaining 20% cyst surface.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CO2 laser vaporization only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CO2 laser vaporization only of the complete inner cystic wall after drainage of the cyst content, irrigation and inspection of its inner wall. Ablation of the inner cyst wall using the CO2 laser (Lumenis). Power settings of 30-55W for CO2 laser beam and 6-10W for CO2 fibre are used. The laser should be on the ablate function to widen the beam (e.g. Surgitouch modus). The laser should be applied in Surgitouch modus so that it can ablate the cyst surface while preserving the underlying healthy tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).</intervention_name>
    <description>cf. different arms</description>
    <arm_group_label>CO2 laser vaporization only</arm_group_label>
    <arm_group_label>The combined technique</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Population: patients planned for laparoscopic CO2 laser surgery for endometriotic cysts.

        Inclusion Criteria:

          -  Age: 18 - 40 years (both inclusive)

          -  Unilateral endometriotic cysts with a mean diameter of &gt;=2.5cm and ≤8 cm, measured in
             3 dimensions.

          -  Presence of a contralateral endometrioma of ≤ 2cm is allowed

          -  Complaining of infertility and/or pain

          -  BMI ≤35

          -  Use of contraception (combined or Progesteron only) for at least 4 weeks before
             surgery

        Exclusion Criteria:

          -  Incomplete surgery for the pelvis

          -  Contra-indication for the use of contraception (combined or Progesteron only)

          -  Use of GnRH analogues preoperatively and in the first 3 months postoperatively

          -  (History of) hysterectomy

          -  Prior unilateral oophorectomy

          -  Pituitary/hypothalamic disorders

          -  Suspected malignancy

          -  Contralateral endometrioma of &gt;2 cm

          -  AMH &lt;0.7 preoperatively

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Tomassetti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leuven University Fertility Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Tomassetti, MD, PhD</last_name>
    <phone>+3216340825</phone>
    <email>carla.tomassetti@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celine Bafort, MD</last_name>
    <phone>+3216340088</phone>
    <email>celine.bafort@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GZA Sint-Augustinus</name>
      <address>
        <city>Antwerp</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brecht Geysenbergh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brecht Geysenbergh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine Bafort, MD</last_name>
      <email>celine.bafort@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Carla Tomassetti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celine Bafort, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Timmermans, Msc</last_name>
    </contact>
    <investigator>
      <last_name>Michelle Nisolle, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Tebache, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

